Abstract:e22507 Background: Methylation-based sequencing has been developed as a promising approach for Multi-Cancer Early Detection (MCED). Conventionally, cancer-specific methylation markers were identified by comparing paired tumor and adjacent normal tissues using traditional algorithm DSS (Dispersion shrinkage for sequencing data). However, the clinical applicability is limited by the unsatisfactory sensitivity in early-stage disease. Hence, we included blood specific markers derived from paired tissue and blood samples and developed a novel fragment-based algorithm in cfDNA with a better signal to noise ratio (SNR) than DSS to improve the sensitivity of the assay. Methods: A total of 391 plasma samples and 433 tissue samples from 7 cancer types were subjected to whole genome bisulfite sequencing (WGBS) (Table). The proportion of stage I-III and stage IV was 3.5:1 among 7 cancer types. The average sequencing depth was 30X. For each bin, the proportion of fully methylated (M) / un-methylated (U) fragments, defined with methylation level ≥85% / ≤15%, was computed individually. One-sided Wilcoxon rank sum test was employed to test whether cancer cfDNA have significantly (FDR < 0.001) higher proportion of U/M fragments than control cfDNA. Results: To evaluate the performance of fragment-based algorithm in cfDNA, the false positive was assessed by resampling from healthy subjects. The healthy cfDNA were randomly assigned 20 times as pseudo case-control groups of 30 /170. The number of markers among healthy samples was recorded as NFalse Positive (NFP), while the number of markers between cancer and healthy samples was recorded as NPositive (NP). SNR was defined as (NP-NFP)/NFP. We calculated SNR using the fragment-based algorithm and achieved SNR of 135.2 for colorectal cancer, compared to SNR of 2.2 using DSS. The improved SNR was also reproduced in other cancer types. Concordance between plasma and tissue markers was 30.09%-95.92% (median 66.72%) among 7 cancer types, which was related to the proportion of ctDNA for each cancer type. Plasma markers which show weak signals in tissue are defined as blood-specific markers. These markers were enriched in immune-related pathways, suggesting a correlation to the immune response of cancer patients. Conclusions: We developed a novel fragment-based algorithm that achieves much higher SNR than DSS in cfDNA. We also identified blood-specific methylation markers which may improve the sensitivity of early cancer detection in clinical. [Table: see text]

MethylPurify: Tumor Purity Deconvolution and Differential Methylation Detection from Single Tumor DNA Methylomes.

MethylPurify: tumor purity deconvolution and differential methylation detection from single tumor DNA methylomes

Estimating and accounting for tumor purity in the analysis of DNA methylation data from cancer studies

Purity Estimation from Differentially Methylated Sites Using Illumina Infinium Methylation Microarray Data.

MEpurity: estimating tumor purity using DNA methylation data.

Predicting tumor purity from methylation microarray data

Detection of differentially methylated CpG sites between tumor samples with uneven tumor purities.

PEIS: a Novel Approach of Tumor Purity Estimation by Identifying Information Sites Through Integrating Signal Based on DNA Methylation Data

Tumor purity quantification by clonal DNA methylation signatures

PESM: A Novel Approach of Tumor Purity Estimation Based on Sample Specific Methylation Sites

Accurately Estimating Tumor Purity Of Samples With High Degree Of Heterogeneity From Cancer Sequencing Data

Wemics: A Single‐Base Resolution Methylation Quantification Method for Enhanced Prediction of Epigenetic Regulation

ExosomePurity: Tumour Purity Deconvolution in Serum Exosomes Based on Mirna Signatures.

Qpure: A Tool to Estimate Tumor Cellularity from Genome-Wide Single-Nucleotide Polymorphism Profiles

A Fragment-Based Algorithm for Identifying Pan-Cancer Differential Methylation Markers from Cfdna.

Tumor detection by analysis of both symmetric- and hemi-methylation of plasma cell-free DNA

Discriminating Origin Tissues of Tumor Cell Lines by Methylation Signatures and Dys-Methylated Rules

A new parsimonious method for classifying Cancer Tissue-of-Origin Based on DNA Methylation 450K data

MethylBERT: A Transformer-based model for read-level DNA methylation pattern identification and tumour deconvolution

Single copy-sensitive electrochemical assay for circulating methylated DNA in clinical samples with ultrahigh specificity based on a sequential discrimination-amplification strategy

Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer